One-year outcomes and secondary prevention in patients after acute minor stroke: results from the China National Stroke Registry
Authors:
- Yuesong PanYPYuesong Pan
- Yongjun WangYWYongjun Wang
- on behalf of the CNSR InvestigatorsOIon behalf of the CNSR Investigators
- 5 May 2017
- journal article
- research article
- Published by Taylor & Francis in Neurological Research
- Vol. 39 (6) , 484-491
Abstract
Objectives: Limited data are available on secondary preventive therapy use and patient outcomes after acute minor ischemic stroke in China. This study investigated secondary prevention strategies and outcomes up to 1 year after minor ischemic stroke. Methods: Patients from the China National Stroke Registry experienced a minor ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5) and admitted to hospital within 24 hours of symptom onset were included. One-year rates of recurrent stroke, stroke-related disability, and all-cause death were evaluated. Risk factors associated with 1-year stroke recurrence were examined in a multivariate model. The secondary prevention strategies in the acute phase were evaluated as combination of secondary prevention medication classes and the medications used in 1 year follow-up were examined. Results: The study included 1913 patients who had experienced acute minor ischemic stroke (mean age: 65.1 years; 67.3% men; mean NIHSS score: 2.5). Rates of recurrent stroke, disability, and death were 13.2, 17.0, and 6.3% at 1 year, respectively. History of hypertension, ischemic stroke, transient ischemic attack, and atrial fibrillation were independent predictors of one-year stroke recurrence. Rate of 1 year all-cause death in patients with triple combined therapy in acute phase was 4.1%, whereas in patients with none was 14.5%. At 1 year, only half patients continued the secondary prevention medications. Conclusions: Outcomes in individuals in China who had experienced acute minor stroke were unfavorable, underscoring the importance of early, sustained preventive therapy in this patient population. Combination of secondary prevention medication classes was associated with a lower risk of death.Keywords
Funding Information
- AstraZeneca (D5134R00007)
- the Ministry of Science and Technology and the Ministry of Health of the People’s Republic of China (2006BA101A11)
- the Ministry of Science and Technology and the Ministry of Health of the People’s Republic of China (2009CB521905)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (D151100002015003)
This publication has 27 references indexed in Scilit:
- The China National Stroke Registry for Patients with Acute Cerebrovascular Events: Design, Rationale, and Baseline Patient CharacteristicsInternational Journal of Stroke, 2011
- Strokes With Minor SymptomsStroke, 2010
- Secondary Prevention of Ischemic Stroke in Urban ChinaStroke, 2010
- Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by riskJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Factors Associated With a High Risk of Recurrence in Patients With Transient Ischemic Attack or Minor StrokeStroke, 2008
- Major Vascular Events after Transient Ischaemic Attack and Minor Ischaemic Stroke: Post Hoc Modelling of Incidence DynamicsCerebrovascular Diseases, 2008
- Stroke in China: epidemiology, prevention, and management strategiesThe Lancet Neurology, 2007
- Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trialThe Lancet, 2006
- In-Hospital Initiation of Secondary Stroke Prevention Therapies Yields High Rates of Adherence at Follow-upStroke, 2004
- Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of servicesBMJ, 2004